Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Claudia Minotto, Davide Griguolo, Luciana Marin, Luca Frison, Fabio D'Amore, Marco Basso, Roberto Sartori, Martina Tinelli, Manuela Stulle, Stefania Fortuna, Angela Bonalumi, Giovanni Bertoldero, Ercole De Biasi, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Giovanni Pizzolo, Mauro Krampera, Mario Tiribelli
The use of generic drugs after patent expiration of their originators is a relative novelty in the treatment of chronic cancer patients in Western countries. In this observational study we analyzed a cohort of 294 Italian chronic phase chronic myeloid leukemia patients treated frontline with branded imatinib (Glivec®) for at least 6 months and then uniformly switched to generic imatinib upon requirement of health authorities in early 2017. Median age at diagnosis was 57 years (range 19-87). Sokal risk was low/intermediate/high in 55%, 32% and 8% of cases, respectively...
November 2018: Leukemia Research